GlassScriptPhysician profile
Michael William Bowers
NPI 1104112119
$1,214.44
in general payments reported to CMS, 2019-2025
17 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $56.05 · 2021: $212 · 2022: $215 · 2023: $156 · 2024: $201 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $573.84 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $218.73 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $216.73 | 2019-2025 | Breztri, Farxiga |
| Lundbeck LLC | $115.72 | 2022-2024 | Rexulti |
| Glaxosmithkline, LLC. | $93.64 | 2020-2024 | Trelegy Ellipta |
| Pfizer INC. | $92.93 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $85.60 | 2019-2025 | Verquvo |
| Supernus Pharmaceuticals, INC. | $71.37 | 2021 | |
| Novo Nordisk INC | $68.94 | 2020-2025 | Rybelsus, Ozempic |
| Corium, LLC | $45.21 | 2024 | Azstarys, Azstarys |
| Novartis Pharmaceuticals Corporation | $42.04 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $41.56 | 2022 | |
| Lilly USA, LLC | $39.33 | 2019-2025 | Zepbound |
| Abbvie INC. | $26.42 | 2023 | Qulipta, Ubrelvy |
| Collegium Pharmaceutical, INC. | $15.19 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $13.99 | 2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $13.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.